Table 1.
Post-hoc characterization of leukocyte differentiation markers
Phenotype | Intended designation |
1. CD45loCD34+ | ISHAGE protocol |
2. Lin-CD45loCD34+ | Hematopoietic progenitors |
3. Lin-CD45loCD34+CD133+CD117+ | Hematopoietic stem cells* |
4. Lin-CD45-CD133+CD31+CD144+KDR+ | Endothelial precursor* |
5. Lin-CD45-CD133-CD31+CD144+KDR+ | Endothelial cell* |
6. CD45+CD10+CD33+HLA-DR-CD45RA- | Myeloid precursor* |
7. CD45+CD10+CD33-HLA-DR+CD45RA+ | Lymphoid precursor* |
8. CD45-CD133+CD146+CD144+CD166+ | Mesenchymal progenitor* |
9. CD45-CD133-CD146+CD73+CD166+ | Mesenchymal cell* |
10. CD45+CD10+CD34+CD19-CD38-TdT+IgM- | pre-pro-B intermediary |
10.1. CD45+CD10+CD34+CD19+CD38-TdT+IgM- | pro-B/pre-B I intermediary |
10.2. CD45+CD10+CD34-CD19+CD38-TdT-IgM- | Pre-B II intermediary |
10.3. CD45+CD10-CD34-CD19+CD38+TdT-IgM+CD24hi | Immature B LΦ |
10.4. CD45+CD10-CD34-CD19+CD38+TdT-IgM+ | Naïve B LΦ |
10.5. CD45+CD10-CD34-CD19+CD38+TdT-IgM+CD24loCD69+ | Mature B LΦ |
11. CD45+CD34+CD38-CD1a-CD3-CD4-CD8- | LΦ-T DN1 |
11.1. CD45+CD34+CD38+CD1a-CD3-CD4-CD8- | LΦ-T DN2 |
11.2. CD45+CD34+CD38+CD1a+CD3-CD4-CD8- | LΦ-T DN3 |
11.3. CD45+CD34+CD38+CD1a+CD3loCD4+CD8- | LΦ-T DN4-ISP |
11.4. CD45+CD34+CD38+CD3-CD4+CD8+ | LΦ-T DP |
11.5. CD45+CD34+CD38+CD3+CD4+CD8+ | LΦ-T DP-CD3 |
12. CD45+CD34+CD3+CD4+CD8- | LΦ-T CD4 |
13. CD45+CD34+CD3+CD4-CD8+ | LΦ-T CD8 |
14. CD45+CD122+CD56+CD3- | NK cells |
15. CD45+CD66acde+ | Neutrophils/Basophils |
16. CD45+CD41a+ | Megakaryocytes |
17. CD45+CD66acde-CD41a-CD14+CD16+ | Monocytes/Macrophages |
*The intended designation to some phenotypes will be more deeply explored with additional markers like CD117, CD31, CD105, CD106, CD166 and others of interest. Besides, cell subpopulations also will be sorted to perform supplementary function assays.